Tiny study probes Insulin's role in fatty liver – could it lead to new treatments?

NCT ID NCT05724134

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 study from Columbia University enrolled 18 overweight or obese adults with insulin resistance and non-alcoholic fatty liver disease (NAFLD). Researchers used a technique called a pancreatic clamp to carefully control insulin levels and measure how blood sugar responds. The goal was to understand the link between high insulin and NAFLD, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Insulin, Octreotide, Glucagon
What this could lead to
If successful, this could help researchers understand the role of high insulin in fatty liver disease, potentially pointing toward new treatment strategies.
What could go wrong
This is a very small, early-phase feasibility study (18 people) designed to test a procedure, not to treat disease. Results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERINSULINEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Columbia University Irving Medical Center

    New York, New York, 10032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.